InterAx Biotech AG
InterAx Biotech AG pioneers computational pharmacology and artificial intelligence for advanced drug discovery focused on G protein-coupled receptors (GPCRs).
About
InterAx Biotech AG is a Swiss spin-out from ETH Zurich and the Paul Scherrer Institute, developing a unique drug discovery platform that integrates biochemistry, cell pathway mathematical modeling, and artificial intelligence. The company specializes in G Protein-Coupled Receptor (GPCR) drug discovery, employing innovative computational and systems biology techniques to design and optimize orally available drugs for complex diseases such as cancer, metabolic, immunological, and neurological disorders. Their technology platform accelerates drug discovery timelines, increases drug efficacy and safety, and supports both lead generation and optimization for proprietary and partnered programs.
Products & Services
- Drug discovery platform for GPCR targets
- High throughput biochemical screening
- AI-driven compound optimization and lead generation
- In vitro and in vivo drug candidate characterization
- Design of novel therapeutics for cancer, inflammation, metabolic, immunological, and neurological indications
- COVID-19 antiviral drug screening assays
Use Cases & Case Studies
- Development of immune-oncology drugs reversing tumor immune evasion (IAX25-Series)
- Oral drug candidates for diabetes and obesity (alternative to peptide injectables)
- Lead generation and validation for multiple sclerosis (remyelination therapies)
- COVID-19 antiviral compound screening and assay development
- GPCR signaling pathway elucidation for improved safety and efficacy of new drugs
Partnerships & Collaborations
- Boehringer Ingelheim (GPCR characterization collaboration)
- Lundbeck A/S (drug candidate characterization)
- GPCR Therapeutics Inc. (compound identification for GPCR heteromers)
- leadXpro AG (immune-oncology targets)
- Vrije Universiteit Amsterdam (chemokine therapeutics, MS and cancer collaborations)
- MS Center Amsterdam (remyelination in MS project)
- Philipps-University Marburg (virtual screening collaboration)
- Prof. Jana Selent IMIM (COVID-19 antiviral research)
- Sosei Heptares (target validation collaboration)
- ONCORNET2.0 EU Training Network (oncogenic GPCR networks)
Awards & Recognition
- Seal of Excellence by European Commission
- TOP 100 Swiss Startup (multiple years)
- Swiss UpStart Challenge Winner
- Venture Kick Final Winner
- Finalist, Swiss Technology Award
- ETH Zürich Pioneer Fellow
- Horizon 2020 SME Instrument Phase I & II recipient
- Horizon Europe EIC Pathfinder grant